Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 197

1.

No Evidence of Systemic Inflammation in Symptomatic Patients with Femoroacetabular Impingement.

Talks BJ, Fernquest S, Palmer A, Broomfield J, Pattinson K, Bradwell A, Glyn-Jones S.

J Orthop Res. 2019 May 20. doi: 10.1002/jor.24348. [Epub ahead of print]

PMID:
31106886
2.

High cutoff versus high-flux haemodialysis for myeloma cast nephropathy in patients receiving bortezomib-based chemotherapy (EuLITE): a phase 2 randomised controlled trial.

Hutchison CA, Cockwell P, Moroz V, Bradwell AR, Fifer L, Gillmore JD, Jesky MD, Storr M, Wessels J, Winearls CG, Weisel K, Heyne N, Cook M.

Lancet Haematol. 2019 Apr;6(4):e217-e228. doi: 10.1016/S2352-3026(19)30014-6. Epub 2019 Mar 11.

PMID:
30872075
3.

Urinary Alpha-1-Acid Glycoprotein Is a Sensitive Marker of Glomerular Protein Leakage at Altitude.

Talks BJ, Bradwell SB, Delamere J, Rayner W, Clarke A, Lewis CT, Thomas OD, Bradwell AR.

High Alt Med Biol. 2018 Sep;19(3):295-298. doi: 10.1089/ham.2018.0017. Epub 2018 Jun 11.

4.

Acetazolamide reduces exercise capacity following a 5-day ascent to 4559 m in a randomised study.

Bradwell AR, Ashdown K, Rue C, Delamere J, Thomas OD, Lucas SJE, Wright AD, Harris SJ, Myers SD; Birmingham Medical Research Expeditionary Society.

BMJ Open Sport Exerc Med. 2018 Jan 23;4(1):e000302. doi: 10.1136/bmjsem-2017-000302. eCollection 2018.

5.

The effect of acetazolamide on saccadic latency at 3459 meters.

Faull OK, Robertson J, Thomas O, Bradwell AR, Antoniades CA, Pattinson KT; Birmingham Medical Research Expeditionary Society.

Wilderness Environ Med. 2015 Mar;26(1):72-7. doi: 10.1016/j.wem.2014.08.017.

PMID:
25712298
6.

Exercise limitation of acetazolamide at altitude (3459 m).

Bradwell AR, Myers SD, Beazley M, Ashdown K, Harris NG, Bradwell SB, Goodhart J, Imray CH, Wimalasena Y, Edsell ME, Pattinson KT, Wright AD, Harris SJ; Birmingham Medical Research Expeditionary Society.

Wilderness Environ Med. 2014 Sep;25(3):272-7. doi: 10.1016/j.wem.2014.04.003. Epub 2014 Jun 13.

PMID:
24931587
7.

Comparative reactivity of human IgE to cynomolgus monkey and human effector cells and effects on IgE effector cell potency.

Saul L, Josephs DH, Cutler K, Bradwell A, Karagiannis P, Selkirk C, Gould HJ, Jones P, Spicer JF, Karagiannis SN.

MAbs. 2014 Mar-Apr;6(2):509-22. doi: 10.4161/mabs.27828. Epub 2014 Jan 14.

8.

Ratio of involved/uninvolved immunoglobulin quantification by Hevylite™ assay: clinical and prognostic impact in multiple myeloma.

Koulieris E, Panayiotidis P, Harding SJ, Kafasi N, Maltezas D, Bartzis V, Tzenou T, Dimou M, Georgiou G, Mirbahai L, Bradwell AR, Kyrtsonis MC.

Exp Hematol Oncol. 2012 Apr 23;1(1):9. doi: 10.1186/2162-3619-1-9.

9.

Immunoglobulin heavy/light chain ratios improve paraprotein detection and monitoring, identify residual disease and correlate with survival in multiple myeloma patients.

Ludwig H, Milosavljevic D, Zojer N, Faint JM, Bradwell AR, Hübl W, Harding SJ.

Leukemia. 2013 Jan;27(1):213-9. doi: 10.1038/leu.2012.197. Epub 2012 Jul 17. Erratum in: Leukemia. 2013 Apr;27(4):996.

10.

Suppression of uninvolved immunoglobulins defined by heavy/light chain pair suppression is a risk factor for progression of MGUS.

Katzmann JA, Clark R, Kyle RA, Larson DR, Therneau TM, Melton LJ 3rd, Benson JT, Colby CL, Dispenzieri A, Landgren O, Kumar S, Bradwell AR, Cerhan JR, Rajkumar SV.

Leukemia. 2013 Jan;27(1):208-12. doi: 10.1038/leu.2012.189. Epub 2012 Jul 11.

11.

Prognostic utility of intact immunoglobulin Ig'κ/Ig'λ ratios in multiple myeloma patients.

Bradwell A, Harding S, Fourrier N, Mathiot C, Attal M, Moreau P, Harousseau JL, Avet-Loiseau H.

Leukemia. 2013 Jan;27(1):202-7. doi: 10.1038/leu.2012.159. Epub 2012 Jun 13.

12.

Commentary.

Bradwell AR.

Clin Chem. 2011 Dec;57(12):1648-9. doi: 10.1373/clinchem.2011.167437. No abstract available.

13.

Acute altitude illnesses.

Imray C, Booth A, Wright A, Bradwell A.

BMJ. 2011 Aug 15;343:d4943. doi: 10.1136/bmj.d4943. Review. No abstract available.

PMID:
21844157
14.

Early reduction of serum-free light chains associates with renal recovery in myeloma kidney.

Hutchison CA, Cockwell P, Stringer S, Bradwell A, Cook M, Gertz MA, Dispenzieri A, Winters JL, Kumar S, Rajkumar SV, Kyle RA, Leung N.

J Am Soc Nephrol. 2011 Jun;22(6):1129-36. doi: 10.1681/ASN.2010080857. Epub 2011 Apr 21.

15.

Novel M-component based biomarkers in Waldenström's macroglobulinemia.

Leleu X, Koulieris E, Maltezas D, Itzykson R, Xie W, Manier S, Dulery R, Boyle E, Gauthier J, Poulain S, Tatiana T, Panayiotidis P, Bradwell AR, Harding S, Leblond V, Kyrtsonis MC, Ghobrial IM.

Clin Lymphoma Myeloma Leuk. 2011 Feb;11(1):164-7. doi: 10.3816/CLML.2011.n.039.

PMID:
21454223
16.

Aggregated serum free light chains may prevent adequate removal by high cut-off haemodialysis.

Harding S, Provot F, Beuscart JB, Cook M, Bradwell AR, Stringer S, White D, Cockwell P, Hutchison CA.

Nephrol Dial Transplant. 2011 Apr;26(4):1438. doi: 10.1093/ndt/gfr019. Epub 2011 Mar 15.

PMID:
21406545
17.

Outcome in renal Al amyloidosis after chemotherapy.

Pinney JH, Lachmann HJ, Bansi L, Wechalekar AD, Gilbertson JA, Rowczenio D, Sattianayagam PT, Gibbs SD, Orlandi E, Wassef NL, Bradwell AR, Hawkins PN, Gillmore JD.

J Clin Oncol. 2011 Feb 20;29(6):674-81. doi: 10.1200/JCO.2010.30.5235. Epub 2011 Jan 10.

PMID:
21220614
18.

Antibodies to human serum amyloid P component eliminate visceral amyloid deposits.

Bodin K, Ellmerich S, Kahan MC, Tennent GA, Loesch A, Gilbertson JA, Hutchinson WL, Mangione PP, Gallimore JR, Millar DJ, Minogue S, Dhillon AP, Taylor GW, Bradwell AR, Petrie A, Gillmore JD, Bellotti V, Botto M, Hawkins PN, Pepys MB.

Nature. 2010 Nov 4;468(7320):93-7. doi: 10.1038/nature09494. Epub 2010 Oct 20.

19.

Differential progression of renal scarring and determinants of late renal recovery in sustained dialysis dependent acute kidney injury secondary to myeloma kidney.

Basnayake K, Cheung CK, Sheaff M, Fuggle W, Kamel D, Nakoinz S, Hutchison CA, Cook M, Stoves J, Bradwell AR, Cockwell P.

J Clin Pathol. 2010 Oct;63(10):884-7. doi: 10.1136/jcp.2010.079236.

PMID:
20876319
20.

Relationship between elevated immunoglobulin free light chain and the presence of IgH translocations in multiple myeloma.

Kumar S, Zhang L, Dispenzieri A, Van Wier S, Katzmann JA, Snyder M, Blood E, DeGoey R, Henderson K, Kyle RA, Bradwell AR, Greipp PR, Rajkumar SV, Fonseca R.

Leukemia. 2010 Aug;24(8):1498-505. doi: 10.1038/leu.2010.128. Epub 2010 Jun 3.

21.

The ratio of parathyroid hormone as measured by third- and second-generation assays as a marker for parathyroid carcinoma.

Cavalier E, Daly AF, Betea D, Pruteanu-Apetrii PN, Delanaye P, Stubbs P, Bradwell AR, Chapelle JP, Beckers A.

J Clin Endocrinol Metab. 2010 Aug;95(8):3745-9. doi: 10.1210/jc.2009-2791. Epub 2010 Jun 2.

22.

Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study.

Dispenzieri A, Katzmann JA, Kyle RA, Larson DR, Melton LJ 3rd, Colby CL, Therneau TM, Clark R, Kumar SK, Bradwell A, Fonseca R, Jelinek DF, Rajkumar SV.

Lancet. 2010 May 15;375(9727):1721-8. doi: 10.1016/S0140-6736(10)60482-5. Erratum in: Lancet. 2010 Jul 31;376(9738):332.

23.

Clinical importance of serum free light chain analysis.

Bradwell AR.

Per Med. 2010 May;7(3):229-231. doi: 10.2217/pme.10.15. No abstract available.

24.

Frequency of altered monoclonal protein production at relapse of multiple myeloma.

Hobbs JA, Drayson MT, Sharp K, Harding S, Bradwell AR, Mead GP.

Br J Haematol. 2010 Feb;148(4):659-61. doi: 10.1111/j.1365-2141.2009.07952.x. Epub 2009 Oct 26. No abstract available.

PMID:
19863537
25.
26.

Assessment of monoclonal gammopathies by nephelometric measurement of individual immunoglobulin kappa/lambda ratios.

Bradwell AR, Harding SJ, Fourrier NJ, Wallis GL, Drayson MT, Carr-Smith HD, Mead GP.

Clin Chem. 2009 Sep;55(9):1646-55. doi: 10.1373/clinchem.2009.123828. Epub 2009 Jul 17.

27.

Monoclonal vs polyclonal free light chain assays.

Legg A, Hobbs JA, Mead GP, Bradwell AR.

Am J Clin Pathol. 2009 Jun;131(6):901-2; author reply 902-3. doi: 10.1309/AJCPBWZD3EFWHNLL. No abstract available.

PMID:
19461100
28.

Staging systems and prognostic factors as a guide to therapeutic decisions in multiple myeloma.

Kyrtsonis MC, Maltezas D, Tzenou T, Koulieris E, Bradwell AR.

Semin Hematol. 2009 Apr;46(2):110-7. doi: 10.1053/j.seminhematol.2009.02.004. Review.

PMID:
19389494
29.

Treatment of acute renal failure secondary to multiple myeloma with chemotherapy and extended high cut-off hemodialysis.

Hutchison CA, Bradwell AR, Cook M, Basnayake K, Basu S, Harding S, Hattersley J, Evans ND, Chappel MJ, Sampson P, Foggensteiner L, Adu D, Cockwell P.

Clin J Am Soc Nephrol. 2009 Apr;4(4):745-54. doi: 10.2215/CJN.04590908. Epub 2009 Apr 1.

30.

Serum free-light chain removal by high cutoff hemodialysis: optimizing removal and supportive care.

Hutchison CA, Harding S, Mead G, Goehl H, Storr M, Bradwell A, Cockwell P.

Artif Organs. 2008 Dec;32(12):910-7. doi: 10.1111/j.1525-1594.2008.00653.x.

PMID:
19133018
31.

Resolution of cast nephropathy following free light chain removal by haemodialysis in a patient with multiple myeloma: a case report.

Basnayake K, Hutchison C, Kamel D, Sheaff M, Ashman N, Cook M, Oakervee H, Bradwell A, Cockwell P.

J Med Case Rep. 2008 Dec 9;2:380. doi: 10.1186/1752-1947-2-380.

32.

Abnormal serum free light chain ratios are associated with poor survival and may reflect biological subgroups in patients with chronic lymphocytic leukaemia.

Pratt G, Harding S, Holder R, Fegan C, Pepper C, Oscier D, Gardiner A, Bradwell AR, Mead G.

Br J Haematol. 2009 Jan;144(2):217-22. doi: 10.1111/j.1365-2141.2008.07456.x. Epub 2008 Nov 11.

PMID:
19016722
33.

Quantitative assessment of serum and urinary polyclonal free light chains in patients with chronic kidney disease.

Hutchison CA, Harding S, Hewins P, Mead GP, Townsend J, Bradwell AR, Cockwell P.

Clin J Am Soc Nephrol. 2008 Nov;3(6):1684-90. doi: 10.2215/CJN.02290508.

34.

European trial of free light chain removal by extended haemodialysis in cast nephropathy (EuLITE): a randomised control trial.

Hutchison CA, Cook M, Heyne N, Weisel K, Billingham L, Bradwell A, Cockwell P.

Trials. 2008 Sep 28;9:55. doi: 10.1186/1745-6215-9-55.

35.

Serum free light chain measurement aids the diagnosis of myeloma in patients with severe renal failure.

Hutchison CA, Plant T, Drayson M, Cockwell P, Kountouri M, Basnayake K, Harding S, Bradwell AR, Mead G.

BMC Nephrol. 2008 Sep 22;9:11. doi: 10.1186/1471-2369-9-11.

36.

AL amyloidosis associated with IgM paraproteinemia: clinical profile and treatment outcome.

Wechalekar AD, Lachmann HJ, Goodman HJ, Bradwell A, Hawkins PN, Gillmore JD.

Blood. 2008 Nov 15;112(10):4009-16. doi: 10.1182/blood-2008-02-138156. Epub 2008 Aug 15.

37.

Free light chains.

Mead GP, Carr-Smith HD, Bradwell AR.

Ann Clin Biochem. 2008 Jul;45(Pt 4):444. doi: 10.1258/acb.2008.072541. No abstract available.

PMID:
18583638
38.

Quantitative assessment of serum and urinary polyclonal free light chains in patients with type II diabetes: an early marker of diabetic kidney disease?

Hutchison CA, Cockwell P, Harding S, Mead GP, Bradwell AR, Barnett AH.

Expert Opin Ther Targets. 2008 Jun;12(6):667-76. doi: 10.1517/14728222.12.6.667 .

PMID:
18479214
39.

Appraisal of immunoglobulin free light chain as a marker of response.

Dispenzieri A, Zhang L, Katzmann JA, Snyder M, Blood E, Degoey R, Henderson K, Kyle RA, Oken MM, Bradwell AR, Greipp PR.

Blood. 2008 May 15;111(10):4908-15. doi: 10.1182/blood-2008-02-138602. Epub 2008 Mar 25.

40.

Serum-free light chain-a new biomarker for patients with B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia.

Martin W, Abraham R, Shanafelt T, Clark RJ, Bone N, Geyer SM, Katzmann JA, Bradwell A, Kay NE, Witzig TE.

Transl Res. 2007 Apr;149(4):231-5.

PMID:
17383597
41.

In reply to Tate et al. Clin Chim Acta 2007;376:30-6.

Robson E, Mead G, Carr-Smith H, Bradwell A.

Clin Chim Acta. 2007 May 1;380(1-2):247; author reply 250-1. Epub 2007 Feb 13. No abstract available.

PMID:
17368602
42.

To the editor: in reply to Nakano et al. Clin Chem Lab Med 2006;44(5):522-532.

Robson E, Mead G, Bradwell A.

Clin Chem Lab Med. 2007;45(2):264-5; author reply 266-7. No abstract available.

PMID:
17311521
43.

Efficient removal of immunoglobulin free light chains by hemodialysis for multiple myeloma: in vitro and in vivo studies.

Hutchison CA, Cockwell P, Reid S, Chandler K, Mead GP, Harrison J, Hattersley J, Evans ND, Chappell MJ, Cook M, Goehl H, Storr M, Bradwell AR.

J Am Soc Nephrol. 2007 Mar;18(3):886-95. Epub 2007 Jan 17.

44.

Outcome of autologous stem cell transplantation for AL amyloidosis in the UK.

Goodman HJ, Gillmore JD, Lachmann HJ, Wechalekar AD, Bradwell AR, Hawkins PN.

Br J Haematol. 2006 Aug;134(4):417-25. Epub 2006 Jul 5.

PMID:
16822290
45.

Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL.

Palladini G, Lavatelli F, Russo P, Perlini S, Perfetti V, Bosoni T, Obici L, Bradwell AR, D'Eril GM, Fogari R, Moratti R, Merlini G.

Blood. 2006 May 15;107(10):3854-8. Epub 2006 Jan 24.

46.

Serum free light chain analysis and urine immunofixation electrophoresis in patients with multiple myeloma.

Nowrousian MR, Brandhorst D, Sammet C, Kellert M, Daniels R, Schuett P, Poser M, Mueller S, Ebeling P, Welt A, Bradwell AR, Buttkereit U, Opalka B, Flasshove M, Moritz T, Seeber S.

Clin Cancer Res. 2005 Dec 15;11(24 Pt 1):8706-14.

47.

The tumor kinetics of multiple myeloma following autologous stem cell transplantation as assessed by measuring serum-free light chains.

Pratt G, Mead GP, Godfrey KR, Hu Y, Evans ND, Chappell MJ, Lovell R, Bradwell AR.

Leuk Lymphoma. 2006 Jan;47(1):21-8.

PMID:
16321823
48.

Serum free light chain (FLC) measurement can aid capillary zone electrophoresis in detecting subtle FLC-producing M proteins.

Bakshi NA, Gulbranson R, Garstka D, Bradwell AR, Keren DF.

Am J Clin Pathol. 2005 Aug;124(2):214-8.

PMID:
16040291
49.

Paraneoplastic neurological antibodies: a laboratory experience.

Karim AR, Hughes RG, Winer JB, Williams AC, Bradwell AR.

Ann N Y Acad Sci. 2005 Jun;1050:274-85.

PMID:
16014543
50.

Efficient breathing circuit for use at altitude.

Pattinson KT, Somogyi RB, Fisher JA, Bradwell AR; Society the Birmingham Medical Research Expeditionary.

Wilderness Environ Med. 2005 Summer;16(2):101-3.

PMID:
15974260

Supplemental Content

Loading ...
Support Center